Precision oncology – are we at an inflection point?
At Molecular Analysis for Precision Oncology (MAP) Congress 2023, international experts discuss the future of histology-agnostic drug development and clinical trial design
Exploiting knowledge of neutrophil protumour and antitumour phenotypes to treat cancer
Identifying the trigger that switches neutrophils from protumour to antitumour activity in the tumour microenvironment could open the door to new therapeutic options
Environmental carcinogens – it’s not all about mutagens
Recent findings regarding the role of tumour promoters in cancer development should lead to a review of the mechanisms of action of existing environmental carcinogens
Cancer Control Principles
Extreme weather, extreme problems in oncology
This summer, photos of New York covered by smoke spread widely catching global attention on the massive wildfires in Canadian forests that caused that apocalyptic scenario. But why should we as oncologists be concerned about such events?
Innovative approaches in the management of gastrointestinal cancers
Molecular characterisation of tumour subtypes and immunotherapy are key areas attracting researchers’ efforts that may shape the future of clinical practice, according to ESMO President Prof. Andrés Cervantes
A growing community
Teresa Del Giudice is the 30,000th ESMO Member. In this interview she explains what motivated her to join the community.
Liquid biopsy in colorectal cancer – the time has come?
Recent findings from studies confirm the promises of ctDNA in this setting, but unanswered questions still remain about timing and methodology
Advanced genetic testing is largely inaccessible to cancer patients across Europe
An ESMO study shows that precision oncology is out of reach for the majority of patients, with costs of technologies and reimbursement policies acting as major barriers
Cancer Research
On the horizon of translational research
Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care
When your patient is the global population
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team